K Clifton1, Yi Min2, J Kimmel2, J Litton2, D Tripathy2, M Karuturi2. 1. The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd. Unit 463, Houston, TX, 77030, USA. kkclifton@mdanderson.org. 2. The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd. Unit 463, Houston, TX, 77030, USA.
Abstract
PURPOSE: Over 40% of newly diagnosed metastatic breast cancer patients are ≥ 70 years old; however, this population is less likely to be represented in clinical trials. The objective of this study was to analyze PFS, dose reductions, dose delays, and toxicity in a geriatric population receiving palbociclib in a non-trial setting. METHODS: Patients with metastatic breast cancer receiving palbociclib in any line of therapy were identified from a cohort of 845 patients at a large academic institution. Dose delays, dose reductions, and toxicities were retrospectively extracted from the medical record. Data were analyzed using Fischer's exact test for categorized variables and T test/Wilcoxon rank-sum test for continuous variables. PFS and OS were analyzed using the Kaplan-Meier method. RESULTS: 605 patients who met eligibility criteria were included. 160 patients were ≥ 65 years old and 92 patients were ≥ 70 years old. Patients ≥ 70 had a significantly increased number of dose reductions (p = 0.03) and dose delays (p = 0.02) compared to the younger patients. There was no significant increase in toxicities, including neutropenic fever, infections, or hospitalizations, in the ≥ 70 cohort (p = 0.3). The ≥ 70 cohort had a significantly improved PFS as compared to the younger cohort (p = 0.02); however, age was no longer a significant variable in the multivariate analysis. CONCLUSIONS: Palbociclib was well tolerated in the geriatric population and there was no difference in PFS between older and younger patients. These results are reassuring as palbociclib becomes the frontline standard of care therapy for patients.
PURPOSE: Over 40% of newly diagnosed metastatic breast cancerpatients are ≥ 70 years old; however, this population is less likely to be represented in clinical trials. The objective of this study was to analyze PFS, dose reductions, dose delays, and toxicity in a geriatric population receiving palbociclib in a non-trial setting. METHODS:Patients with metastatic breast cancer receiving palbociclib in any line of therapy were identified from a cohort of 845 patients at a large academic institution. Dose delays, dose reductions, and toxicities were retrospectively extracted from the medical record. Data were analyzed using Fischer's exact test for categorized variables and T test/Wilcoxon rank-sum test for continuous variables. PFS and OS were analyzed using the Kaplan-Meier method. RESULTS: 605 patients who met eligibility criteria were included. 160 patients were ≥ 65 years old and 92 patients were ≥ 70 years old. Patients ≥ 70 had a significantly increased number of dose reductions (p = 0.03) and dose delays (p = 0.02) compared to the younger patients. There was no significant increase in toxicities, including neutropenic fever, infections, or hospitalizations, in the ≥ 70 cohort (p = 0.3). The ≥ 70 cohort had a significantly improved PFS as compared to the younger cohort (p = 0.02); however, age was no longer a significant variable in the multivariate analysis. CONCLUSIONS:Palbociclib was well tolerated in the geriatric population and there was no difference in PFS between older and younger patients. These results are reassuring as palbociclib becomes the frontline standard of care therapy for patients.
Entities:
Keywords:
CDK 4/6 inhibitors; Hormone receptor-positive breast cancer; Metastatic breast cancer; Treatment toxicity
Authors: Angelica P Herrera; Shedra Amy Snipes; Denae W King; Isabel Torres-Vigil; Daniel S Goldberg; Armin D Weinberg Journal: Am J Public Health Date: 2010-02-10 Impact factor: 9.308
Authors: Søren M Johnson; Chad D Torrice; Jessica F Bell; Kimberly B Monahan; Qi Jiang; Yong Wang; Matthew R Ramsey; Jian Jin; Kwok-Kin Wong; Lishan Su; Daohong Zhou; Norman E Sharpless Journal: J Clin Invest Date: 2010-06-23 Impact factor: 14.808
Authors: Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon Journal: Lancet Oncol Date: 2014-12-16 Impact factor: 41.316
Authors: Nadia Howlader; Sean F Altekruse; Christopher I Li; Vivien W Chen; Christina A Clarke; Lynn A G Ries; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2014-04-28 Impact factor: 13.506
Authors: Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466
Authors: David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood Journal: Mol Cancer Ther Date: 2004-11 Impact factor: 6.261
Authors: Danielle B Tometich; Kelly A Hyland; Hatem Soliman; Heather S L Jim; Laura Oswald Journal: Cancers (Basel) Date: 2020-12-08 Impact factor: 6.639